Sunday, July 05, 2020 8:07:52 PM
Thanks.
I was impressed with the interview and with the man. Therefore I had a better understanding what he's trying to accomplish and how he expects to get it done.
Make no mistake, I am not all in but I'm prepared to be patient now. So when I do execute a Buy it'll be similar in shares to the shares I sold. And I have no reservation of paying more if need be and if the momentum is with me as are the indicators I use.
It's still "Game On" . So now , as he opened up on this interview and answered all the questions squarely and comprehensively, with extreme candor and professionalism, I'm over the 50 yard line in at least field goal range.
Now it's time for more progress which gives clues ( via updates) that the company is near the end zone.
That and Technicals will go along way in convincing me 100%
This weeks trading activity and patterns will be quite interesting. Support levels that I suggested are still in place ie $5.75 and $4.70ish.Doesn't mean the stock will go there; simply means it's where technicals suggest it'll find support
Resistance remains at about $7.05+. Doesn't mean it won't bust through it either. My gut tell me the stock will be doing a backing and filling for awhile ( sideways within a range) before the next move of substance. I'm betting it will be a move up.
I was impressed with the interview and with the man. Therefore I had a better understanding what he's trying to accomplish and how he expects to get it done.
Make no mistake, I am not all in but I'm prepared to be patient now. So when I do execute a Buy it'll be similar in shares to the shares I sold. And I have no reservation of paying more if need be and if the momentum is with me as are the indicators I use.
It's still "Game On" . So now , as he opened up on this interview and answered all the questions squarely and comprehensively, with extreme candor and professionalism, I'm over the 50 yard line in at least field goal range.
Now it's time for more progress which gives clues ( via updates) that the company is near the end zone.
That and Technicals will go along way in convincing me 100%
This weeks trading activity and patterns will be quite interesting. Support levels that I suggested are still in place ie $5.75 and $4.70ish.Doesn't mean the stock will go there; simply means it's where technicals suggest it'll find support
Resistance remains at about $7.05+. Doesn't mean it won't bust through it either. My gut tell me the stock will be doing a backing and filling for awhile ( sideways within a range) before the next move of substance. I'm betting it will be a move up.
Recent CYDY News
- CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2026 01:35:02 PM
- CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab • GlobeNewswire Inc. • 03/05/2026 01:30:00 PM
- CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference • GlobeNewswire Inc. • 02/20/2026 01:30:00 PM
- CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer • GlobeNewswire Inc. • 01/27/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/09/2026 10:15:22 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/09/2026 01:30:45 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/22/2025 10:15:23 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/17/2025 05:15:14 AM
- December 2025 Letter to Shareholders • GlobeNewswire Inc. • 12/16/2025 01:30:00 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 12/10/2025 10:16:32 PM
- CytoDyn to Showcase PD-L1 Upregulation and Improved Survival in Metastatic Triple Negative Breast Cancer at the San Antonio Breast Cancer Symposium • GlobeNewswire Inc. • 12/08/2025 01:30:00 PM
